1

P E R S O N A L I S E D D I G I TA L H E A LT H I N T E R V E N T I O N

F O R E V E R Y C A N C E R PAT I E N T

2

C O N F I D E N T I A L

Solving high unmet medical need in oncology

C A N C E R

I N C I D E N C E I N C R E A S I N G

P R E C I S I O N M E D I C I N E A N D P E R S O N A L I S E D

T H E R A P I E S T O B E N E F I T P A T I E N T S

T H E R E ’ S A H I G H U N M E T M E D I C A L N E E D F O R T I M E LY M A N A G E M E N T O F T O X I C I T I E S O F T H E P R E C I S I O N

C O M B I N AT I O N T H E R A P I E S I N O R D E R T O P R O V I D E P AT I E N T S W I T H T H E M O S T O P T I M I Z E D T R E AT M E N T S

A N D T O F O L L O W O N O U T C O M E S A N D S A F E T Y I N R E A L - T I M E .

The global cancer incidence was estimated to have risen to over 18

million new cases in 2018 according to the WHO.

Several targeted therapies, such as immune checkpoint inhibitor (ICI) and

tyrosine kinase inhibitor (TKI) therapies and combinations with precision

radiation, have drastically changed the treatment landscape of 1st and 2nd

line treatments across several indications.

3

Solution: Personalised digital healthintervention for everycancer patient

C E - M A R K E D C L A S S I M E D I C A L D E V I C E ( M D R : C L A S S I I A )

Treatment modality specific algorithms screen

symptoms and real-world data, alert care team

and provide personalised support for patients.

C O N F I D E N T I A L

44

R E F E R E N C E S

Co-created in Routine Cancer Care

Leading European hospitals and clinics are using our platform to better monitor their patients, reducing manual work and allowing prioritization of clinical

actions.

C O N F I D E N T I A L

55

40+ 4000+Oncology care units in Germany, Switzerland,

Finland, Sweden and Italy

G R O W I N G

G L O B A L F O O T P R I N T

Today

Next GEOs

100 000+Accumulated patients supported cross indication (cancer care, fertility

treatment and preventive healthcare) proving scalable implementation

power and excellent usability with volumes

Cancer patients

C O N F I D E N T I A L

66

Evidence from literature: A randomized controlled trial with 766 metastatic cancer

patients shows that digital symptom monitoring (non-commercial research tool)

during chemotherapy helps patients live longer (5.2 months longer median overall

survival), improves quality of life (31% of patients), and reduces hospitalization (4%)

and ER visits (7%).

Novel results from Kaiku Health’s real-world data: the first study in the world to publish real-world

data gathered by Kaiku Health’s Immune Checkpoint Inhibitor module show correlations between

different symptoms, which might reflect therapeutic efficiency, side effects, or tumor progression. A

prospective feasibility trial validating Kaiku Health’s Immune Checkpoint Inhibitor module is expected

to be published H2/2019.

Digital therapeutics show a significant potential for improving clinicaloutcomes in oncology

S C I E N T I F I C E V I D E N C E C O N F I D E N T I A L

7

T H E R A P Y M O D A L I T Y I N D I C A T I O N P R O G R A M D I S C O V E R Y P R O O F - O F - C O N C E P T F D A P R E S U B P I V O T A L S T U D Y R E G U L A T O R Y

C L E A R A N C E

P H A R M A C O L L A B O R A T I O N

P R O J E C T S

Immune checkpointInhibitor therapies

Lung KH-001

Melanoma KH-002

Genitourinary KH-003

Others

Chemo-, targeted and hormonal therapies

Multiplemyeloma

KH-004

Colorectal cancer KH-005 To be disclosed

Prostate cancer KH-006

Generic KH-007

CAR T-Cell therapies In Search

TKI, PARP, BRAF/MEK, CDK4 / 6 therapies

In Search

Radiotherapy and surgery*

Strong pharma DTx and RWD collaboration pipelineK

AIK

U H

EA

LT

H D

Tx

PL

AT

FO

RM

Algorithm Engine

C O N F I D E N T I A L

(Independent + Companion)

*Indication specific programs in radiotherapy and surgery.

8

Investment history

S E E D R O U N D : P R O D U C T D E V E L O P M E N T A R O U N D : M A R K E T E X PA N S I O N

S I Z E 1 7 7 0 0 0 0 € 4 4 0 0 0 0 0 €

I N V E S T O R S Reaktor Ventures and Angel Investors (e.g. Jaakko Ollila,

Mario Huyghe, Kustaa Piha), Business Finland (grant)

Debiopharm Innovation Fund, TESI, Reaktor Ventures, Jaakko

Ollila, Kustaa Piha, Prodeko Ventures

O U T C O M E Launch of Kaiku Health cancer care modules and scaling

to other therapy fields. Starting clinical validation of cancer

immunotherapy algorithm.

Successful introduction of Kaiku Health to European markets and

launch of first global deals with pharmaceutical companies.

Successful competition

of pilot studies and first RCT protocol finalized.

C O N F I D E N T I A L

9

V I S I O N

Personalised digital health interventionfor every cancer patient

C O N F I D E N T I A L

10

L A U R I S I P P O L A , C E O & C O - F O U N D E R

E M A I L : L A U R I . S I P P O L A @ K A I K U H E A LT H . C O M

T E L . + 3 5 8 4 0 7 4 4 7 4 8 1

C O N F I D E N T I A L

Thank you!